This is a routine corporate update with no new data. The key near-term catalyst is the HS Phase 2 topline readout in Q4 2026. Monitor for any data disclosures or trial updates ahead of that timeline.
Price Chart
Executive Summary
Zura Bio filed an 8-K furnishing an updated corporate investor presentation (Exhibit 99.1) as Regulation FD disclosure. The presentation details the company's pipeline, focusing on its lead bispecific antibody tibulizumab (targeting IL-17 and BAFF) in Phase 2 trials for hidradenitis suppurativa (HS) and systemic sclerosis (SSc), with topline data expected in Q4 2026 and H1 2027, respectively. The company reported $205.1M in cash as of June 30, 2026, providing a runway through at least year-end 2028, and highlighted upcoming catalysts including a planned Phase 2 PMR trial initiation by year-end 2026.
Key Facts
- Zura Bio provided an updated corporate presentation via 8-K Item 7.01.
- Lead candidate tibulizumab (anti-BAFF/IL-17 bispecific) is in Phase 2 for HS (TibuSHIELD, readout Q4 2026) and SSc (TibuSURE, readout H1 2027).
- Phase 2 PMR study (NEXUS-PMR) planned to initiate by year-end 2026.
- Cash and cash equivalents: $205.1M as of 6/30/26, with cash runway through at least year-end 2028.
- Total shares outstanding: 124.7M (95.4M common stock + 29.3M pre-funded warrants).
- The filing is a routine investor presentation update with no new financial results or material definitive agreements.
Financial Impact
No new financial results reported. Cash position of $205.1M as of 6/30/26 disclosed.
Risk Factors
- Clinical trial failure risk for tibulizumab in HS, SSc, or PMR.
- Pre-revenue biotech with no approved products; requires additional capital beyond current runway.
- Competitive landscape includes approved IL-17 inhibitors (Cosentyx, Taltz, Bimzelx) and other novel therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-097526 |
| Document: tm2623351d1_8k.htm | 0001104659-26-097526 |
| Document: 0001104659-26-097526-index-headers.html | 0001104659-26-097526 |
| Document: 0001104659-26-097526-index.html | 0001104659-26-097526 |
| Document: 0001104659-26-097526.txt | 0001104659-26-097526 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $3.35 | awaiting T+20 | — | $3.48 (+3.88%) |
Aug 17, 2026 10w ago | 8-K | $5.68 $4.93 | ▼ −13.20% | ▼ −11.23% | $3.48 (−38.73%) |
Aug 11, 2026 11w ago | 8-K | $5.56 $5.71 | ▲ +2.70% | ▲ +3.76% | $3.48 (−37.41%) |
Jul 1, 2026 16w ago | 8-K | $5.01 $5.31 | ▲ +6.09% | ▲ +8.28% | $3.48 (−30.47%) |
Jun 18, 2026 18w ago | 8-K | $4.23 $5.45 | ▲ +28.84% | ▲ +28.99% | $3.48 (−17.73%) |
May 7, 2026 24w ago | 8-K | $4.54 $3.86 | ▼ −14.98% | ▼ −18.11% | $3.48 (−23.35%) |
Mar 5, 2026 33w ago | 8-K | $6.76 $6.03 | ▼ −10.80% | ▼ −7.01% | $3.48 (−48.52%) |
Feb 26, 2026 34w ago | 8-K | $6.77 $6.04 | ▼ −10.78% | ▼ −4.38% | $3.48 (−48.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers